Chris Ryan
A federal jury in Delaware has reportedly found that Japan's Nippon Shinyaku infringed Sareptino (NASDAQ:JULY) patented its Duchenne muscular dystrophy, or DMD, drug Vyondys 53 and awarded Sarept $115.2 million in damages.
The jury also rejected Shinyaku's claim